Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

NR4A3 rearrangement + KIT mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

KIT mutation (32)

KIT exon 11 mutation (13)

KIT exon 9 mutation (9)

KIT exon 13 mutation (6)

KIT exon 17 mutation (6)

KIT wild-type (3)

KIT W557_V559delinsF (2)

KIT exon 11 mutation + KIT exon 17 mutation (2)

KIT exon 18 mutation (2)

KIT exon 8 mutation (2)

BRAF G466V + KIT K509Q (1)

KDR Q472H + KIT M541L (1)

KIT M552_V555delMYEV (1)

KIT V559A + KIT N822I (1)

KIT V559_E561del (1)

KIT W557_V559>C (1)

KIT W557_V559>F (1)

KIT exon 11 W557_K558delins (1)

KIT exon 14 mutation (1)

KIT exon 17 mutation + KIT exon 18 mutation (1)

KIT translocation (1)

KIT rs3733542 (0)

KIT mutation (32)

KIT exon 11 mutation (13)

KIT exon 9 mutation (9)

KIT exon 13 mutation (6)

KIT exon 17 mutation (6)

KIT wild-type (3)

KIT W557_V559delinsF (2)

KIT exon 11 mutation + KIT exon 17 mutation (2)

KIT exon 18 mutation (2)

KIT exon 8 mutation (2)

BRAF G466V + KIT K509Q (1)

KDR Q472H + KIT M541L (1)

KIT M552_V555delMYEV (1)

KIT V559A + KIT N822I (1)

KIT V559_E561del (1)

KIT W557_V559>C (1)

KIT W557_V559>F (1)

KIT exon 11 W557_K558delins (1)

KIT exon 14 mutation (1)

KIT exon 17 mutation + KIT exon 18 mutation (1)

KIT translocation (1)

KIT rs3733542 (0)

›

over3years

Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation. (PubMed, BMJ Case Rep)

The patient has been on imatinib, a tyrosine kinase inhibitor with activity against KIT, for 3 years with stable disease. Metastatic EMC is generally treated with surgical resection and perioperative radiation therapy with adjuvant chemotherapy and is associated with poor prognosis.

over 3 years ago

Clinical • Journal

|

KIT (KIT proto-oncogene, receptor tyrosine kinase) • NR4A3 (Nuclear receptor subfamily 4 group A member 3)

|

KIT mutation • KIT exon 11 mutation • NR4A3 rearrangement + KIT mutation

|

imatinib